RaQualia Pharma Inc.

Tokyo Stock Exchange:4579.T

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🐶 Pet Food

💊 Pharmaceuticals

Location

Japan

Market Cap

USD 103.40 M

Share Price

USD 4.23

Avg Daily Volume

298,219

Change (1 day)

-0.84%

Change (1 year)

9.20%

Change (YTD)

73.00%

RaQualia Pharma Inc. Inventory for the year ending December 31, 2024: USD 1.07 M

RaQualia Pharma Inc. Inventory is USD 1.07 M for the year ending December 31, 2024, a 1.74% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.

RaQualia Pharma Inc. Inventory for the year ending December 31, 2023 was USD 1.05 M, a 1,517.87% change year over year.
RaQualia Pharma Inc. Inventory for the year ending December 31, 2022 was USD 64.80 K, a -29.26% change year over year.
RaQualia Pharma Inc. Inventory for the year ending December 31, 2021 was USD 91.61 K, a 44.75% change year over year.
RaQualia Pharma Inc. Inventory for the year ending December 31, 2020 was USD 63.29 K, a 25.07% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Inventory	Current Assets	Property, Plant, Equipment (Net)	Total Assets

Tokyo Stock Exchange: 4579.T

RaQualia Pharma Inc.

CEO	Masaki Sudo
IPO Date	July 20, 2011
Location	Japan
Headquarters	Meieki Southside Square
Employees	64
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🐶 Pet Food 💊 Pharmaceuticals

Description

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.